16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second benefit assessment than in the first.
The Federal Joint Committee (G-BA) certified a "considerable" additional benefit on the basis of a so-called indirect comparison with the standard therapy.
In its assessment, the G-BA examined whether nivolumab is better than standard therapy as a supportive treatment after surgery for black skin cancer with lymph node involvement or metastases.